Floatz logo

Durvalumab

Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow Universitymonoclonal_antibodyPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Advanced Refractory Solid Tumors cohort.

Asset / SponsorPhaseRating
Sugemalimab
Second Affiliated Hospital of Soochow University
Phase 2BB
Gm-Csf
Second Affiliated Hospital of Soochow University
Phase 2B
Talzenna
St. Jude Children's Research Hospital
Phase 2B
Regorafenib
China Medical University, China
Phase 1/2CCC
Selinexor
National University Hospital, Singapore
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →